Ipatasertib
- Generic Name
- Ipatasertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32ClN5O2
- CAS Number
- 1001264-89-6
- Unique Ingredient Identifier
- 524Y3IB4HQ
- Background
Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast Cancer, and Gastric Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Jun Zhang, MD, PhD
- Target Recruit Count
- 60
- Registration Number
- NCT04467801
- Locations
- 🇺🇸
The University of Kansas Cancer Center (KUCC), Fairway, Kansas, United States
🇺🇸The University of Kansas Cancer Center, Lee's Summit Clinic, Lee's Summit, Missouri, United States
🇺🇸The University of Kansas Cancer Center, Overland Park Clinic, Overland Park, Kansas, United States
Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 54
- Registration Number
- NCT04464174
- Locations
- 🇪🇸
Hospital Quiron San Camilo- Ruber Juan Bravo, Madrid, Spain
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain
🇵🇹Champalimaud Clinical Centre - Champalimaud Foundation, Lisboa, Portugal
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
- Conditions
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT04404140
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
🇪🇸Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain
🇫🇷Centre Val Aurelle Paul Lamarque; Radiotherapie, Montpellier, France
A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT04341259
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai City, China
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 15
- Registration Number
- NCT04253561
- Locations
- 🇪🇸
ICO Badalona, Badalona, Barcelona, Spain
🇪🇸Comp. Hosp.Univ. Santiago (Chus), Santiago De Compostela, La Coruña, Spain
🇪🇸Hospital Universitario del Vall d' Hebron, Barcelona, Spain
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 242
- Registration Number
- NCT04177108
- Locations
- 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇨🇦McGill University; Glen Site; Oncology, Montreal, Quebec, Canada
🇨🇦Royal Victoria Hospital, Barrie, Ontario, Canada
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT04060862
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇨🇦Hopital du Saint Sacrement, Quebec City, Quebec, Canada
🇺🇸Dana-Farber Cancer Institute; GYN Oncology, Boston, Massachusetts, United States
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 77
- Registration Number
- NCT03959891
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 28
- Registration Number
- NCT03853707
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
- Conditions
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT03840200
- Locations
- 🇦🇺
Macquarie University Hospital, Macquarie Park, New South Wales, Australia
🇪🇸ClÃnica Universidad de Navarra, Pamplona, Navarra, Spain
🇮🇹Azienda Ospedaliera Santa Maria di Terni, Terni, Umbria, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.